Merrill sees low EPS for Genyzme

Merrill Lynch analyst Eric Ende believes Street expectations for Genzyme Corp. are low due to a lack of prescription data availability, as well as light first-quarter revenues for Fabrazyme and Synvisc. Seasonal weakness for Synvisc should turn to seasonal strength in the second quarter. Renagel sales remain a wildcard, according to the analyst. Shares of the Cambridge, Mass.-based biotechnology company were down 65 cents, or 1.10%, at $58.71 on volume of 2,371,016 shares versus the three-month running average of 3,173,660 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.